Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T29143
|
||||
| Former ID |
TTDC00177
|
||||
| Target Name |
Interleukin-13
|
||||
| Gene Name |
IL13
|
||||
| Synonyms |
IL-13; IL13
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Allergic asthma [ICD9: 493, 995.3; ICD10: J45, T78.4] | ||||
| Allergic rhinitis [ICD9: 472.0, 477, 995.3; ICD10: J00, J30, J31.0, T78.4] | |||||
| Asthma; Ulcerative colitis [ICD10: J45, K51] | |||||
| Allergy [ICD9: 995.3; ICD10: T78.4] | |||||
| Asthma; Atopic eczema [ICD10: J45, L20-L30] | |||||
| Asthma; Chronic obstructive pulmonary disease [ICD9: 490-492, 493, 494-496; ICD10: J40-J44, J47, J45] | |||||
| Idiopathic pulmonary fibrosis [ICD9: 516.3; ICD10: J84.1] | |||||
| Severe asthma [ICD9: 493; ICD10: J45] | |||||
| Function |
Cytokine. Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses.
|
||||
| BioChemical Class |
Cytokine: interleukin
|
||||
| Target Validation |
T29143
|
||||
| UniProt ID | |||||
| Sequence |
MHPLLNPLLLALGLMALLLTTVIALTCLGGFASPGPVPPSTALRELIEELVNITQNQKAP
LCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRD TKIEVAQFVKDLLLHLKKLFREGRFN |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Lebrikizumab | Drug Info | Phase 3 | Severe asthma | [1], [2] |
| Anrukinzumab | Drug Info | Phase 2 | Asthma; Ulcerative colitis | [3], [4], [5] | |
| Lebrikizumab | Drug Info | Phase 2 | Asthma; Chronic obstructive pulmonary disease | [6], [7], [8], [9] | |
| PEGylated pitrakinra | Drug Info | Phase 2 | Asthma; Atopic eczema | [10], [11] | |
| QAX-576 | Drug Info | Phase 2 | Allergic rhinitis | [12] | |
| SAR156597 | Drug Info | Phase 2 | Idiopathic pulmonary fibrosis | [13] | |
| CNTO-5825 | Drug Info | Phase 1 | Allergic asthma | [14] | |
| PEGylated pitrakinra | Drug Info | Investigative | Allergy | [15] | |
| Modulator | Anrukinzumab | Drug Info | |||
| Lebrikizumab | Drug Info | [15] | |||
| PEGylated pitrakinra | Drug Info | [15] | |||
| QAX-576 | Drug Info | [16] | |||
| SAR156597 | Drug Info | [17] | |||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Jak-STAT signaling pathway | |||||
| Fc epsilon RI signaling pathway | |||||
| Measles | |||||
| Asthma | |||||
| Inflammatory bowel disease (IBD) | |||||
| NetPath Pathway | IL9 Signaling Pathway | ||||
| TCR Signaling Pathway | |||||
| IL2 Signaling Pathway | |||||
| Leptin Signaling Pathway | |||||
| TSLP Signaling Pathway | |||||
| PANTHER Pathway | Interleukin signaling pathway | ||||
| Pathway Interaction Database | Glucocorticoid receptor regulatory network | ||||
| IL12 signaling mediated by STAT4 | |||||
| PathWhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | ||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Cytokines and Inflammatory Response | |||||
| Allograft Rejection | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01875003) A Study of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7684). | ||||
| REF 3 | ClinicalTrials.gov (NCT00425061) Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma. U.S. National Institutes of Health. | ||||
| REF 4 | ClinicalTrials.gov (NCT00410280) Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma | ||||
| REF 5 | ClinicalTrials.gov (NCT01284062) Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients | ||||
| REF 6 | ClinicalTrials.gov (NCT00930163) A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids | ||||
| REF 7 | ClinicalTrials.gov (NCT00971035) A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids | ||||
| REF 8 | ClinicalTrials.gov (NCT01987492) A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma | ||||
| REF 9 | ClinicalTrials.gov (NCT02546700) A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | ||||
| REF 10 | ClinicalTrials.gov (NCT00676884) A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema | ||||
| REF 11 | ClinicalTrials.gov (NCT00801853) A Study of the Treatment-Sparing Effects of AEROVANT?AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL | ||||
| REF 12 | ClinicalTrials.gov (NCT01266135) Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health. | ||||
| REF 13 | ClinicalTrials.gov (NCT02345070) Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis | ||||
| REF 14 | ClinicalTrials.gov (NCT01081691) A Study Evaluating Intravenous and Subcutaneous Administration of a Human Monoclonal Antibody (CNTO 5825) in Healthy Volunteers. U.S. National Institutes of Health. | ||||
| REF 15 | The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. doi: 10.1038/nrd3792. | ||||
| REF 16 | Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7. | ||||
| REF 17 | Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. doi: 10.1038/nrd4478. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.